Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.54 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MPI | P34949 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1780443 | 0.87 | KDM4E (0.59) | POLBKDM4EALDH1A1ALOX15BCHE | |
| SCHEMBL4324895 | 0.87 | ALOX15 (0.60) | POLBKDM4EALDH1A1ALOX15BCHE | |
| SCHEMBL11474990 | 0.86 | BCHE (0.59) | POLBKDM4EALDH1A1ALOX15BCHE | |
| SCHEMBL1780354 | 0.86 | ALDH1A1 (0.59) | POLBKDM4EALDH1A1ALOX15BCHE | |
| 4,4-Diantipyrylmethane Monohydrate SCHEMBL3879841 | 0.85 | ALOX15 (0.62) | POLBKDM4EALDH1A1ALOX15BCHE | |
| 4,4-Diantipyrylmethane Monohydrate SCHEMBL8664775 | 0.83 | ALOX15 (0.60) | POLBKDM4EALDH1A1ALOX15BCHE | |
| SCHEMBL2966930 | 0.82 | ALOX15 (0.63) | POLBKDM4EALDH1A1ALOX15BCHE | |
| SCHEMBL28049673 | 0.82 | BCHE (0.63) | POLBKDM4EALDH1A1ALOX15BCHE | |
| SCHEMBL22689599 | 0.81 | KDM4E (0.63) | POLBKDM4EALDH1A1ALOX15BCHE | |
| SCHEMBL28434462 | 0.80 | BCHE (0.56) | POLBKDM4EALDH1A1ALOX15BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200140290-A1 | Remediation of physiologically active compounds from waste water | SECURE NATURAL RESOURCES LLC (US) | 2020-05-07 | — | — | US | claimed |
| US-20140024697-A1 | CO-CRYSTALS OF DULOXETINE AND COX-INHIBITORS FOR THE TREATMENT OF PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2014-01-23 | — | — | US | claimed |
| US-8501802-B2 | Co-crystals of duloxetine and COX-INHIBITORs for the treatment of pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-08-06 | — | — | US | claimed |
| EP-2580165-A1 | REMEDIATION OF PHYSIOLOGICALLY ACTIVE COMPOUNDS FROM WASTE WATER | Molycorp Minerals, LLC (US) | 2013-04-17 | — | — | EP | claimed |
| US-20110160273-A1 | CO-CRYSTALS OF DULOXETINE AND COX-INHIBITORS FOR THE TREATMENT OF PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2011-06-30 | — | — | US | claimed |
| EP-2291345-A1 | CO-CRYSTALS OF DULOXETINE AND COX-INHIBITORS FOR THE TREATMENT OF PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-03-09 | — | — | EP | claimed |
| WO-2011015360-A1 | PHARMACEUTICAL COMPOUNDS OF O-DESMETHYL-TRAMADOL AND COX-INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-02-10 | — | — | WO | claimed |
| EP-2281558-A1 | Pharmaceutical compounds of O-Desmethyl-Tramadol and COX-inhibitors | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-02-09 | — | — | EP | claimed |
| WO-2009141144-A1 | CO-CRYSTALS OF DULOXETINE AND COX-INHIBITORS FOR THE TREATMENT OF PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-11-26 | — | — | WO | claimed |
| EP-2123626-A1 | Co-crystals of duloxetine and co-crystal formers for the treatment of pain | Laboratorios del Dr. Esteve S.A. (ES) | 2009-11-25 | — | — | EP | claimed |
| US-6849623-B2 | Xanthine and phenazone-acesulfame-H complexes having improved taste, process for their preparation and their use | NUTRINOVA NUTRITION SPECIALTIES & FOOD INGREDIENTS GMBH (DE) | 2005-02-01 | — | — | US | claimed |
| EP-1200521-B1 | DISPERSION COMPRISING A NON-IONIC EMULSIFIER | ROEHM GMBH (DE) | 2004-11-10 | — | — | EP | claimed |
| EP-1270573-B1 | Xanthine and phenazone acesulfam-H complexes with improved taste, process for their preparation and their use | NUTRINOVANUTRITION SPECIALTIES (DE) | 2004-09-01 | — | — | EP | claimed |
| US-20030119909-A1 | Stabilized medicament containing cysteinyl derivatives | STANISLAUS, FRITZ (DE) | 2003-06-26 | — | — | US | claimed |
| US-20030008865-A1 | Xanthine-and phenazone-acesulfame-H complexes having improved taste, process for their preparation and their use | NUTRINOVA NUTRITION SPECIALTIES & FOOD INGREDIENTS GMBH (DE) | 2003-01-09 | — | — | US | claimed |
| EP-1270573-A1 | Xanthine and phenazone acesulfam-H complexes with improved taste, process for their preparation and their use | Nutrinova Nutrition Specialties & Food Ingredients GmbH (DE) | 2003-01-02 | — | — | EP | claimed |
| US-20020037855-A1 | Stabilized medicament containing cysteinyl derivatives | STANISLAUS FRITZ (DE) | 2002-03-28 | — | — | US | claimed |
| EP-1067942-A1 | HIGH-ENERGY CYCLODEXTRIN COMPLEXES | Cyclops, EHF. (IS) | 2001-01-17 | — | — | EP | claimed |
| WO-1999042111-A1 | HIGH-ENERGY CYCLODEXTRIN COMPLEXES | CYCLOPS, EHF. (IS) | 1999-08-26 | — | — | WO | claimed |
| WO-1998052616-A2 | NONSTEROIDAL ANTIRHEUMATIC AGENTS OR THROMBOCYTE-AGGLUTINATION INHIBITORS TO IMPROVE REPRESENTATION OF VESSELS, LYMPH NODES AND BONE MARROW WITH PHARMACEUTICAL PREPARATIONS CONTAINING PARTICLES, VESICLES OF POLYMERS | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin (DE) | 1998-11-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024697-A1 | CO-CRYSTALS OF DULOXETINE AND COX-INHIBITORS FOR THE TREATMENT OF PAIN | OPRL1, OPRK1, HTR5A | POLB 4497/4885KDM4E 1367/4885ALDH1A1 531/4885 |
| US-20110160273-A1 | CO-CRYSTALS OF DULOXETINE AND COX-INHIBITORS FOR THE TREATMENT OF PAIN | OPRL1, OPRK1, HTR5A | POLB 4497/4885KDM4E 1367/4885ALDH1A1 531/4885 |
| US-20030008865-A1 | Xanthine-and phenazone-acesulfame-H complexes having improved taste, process for their preparation and their use | PDXK, XDH, ACE | POLB 1342/4885KDM4E 1582/4885ALDH1A1 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.